| Autor: |
Baddini-Martinez J; Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto (SP) Brasil.; Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo (SP) Brasil., Ferreira J; Faculdade de Medicina, Universidade de São Paulo, São Paulo (SP) Brasil., Tanni S; Faculdade de Medicina de Botucatu, Universidade Estadual Paulista - UNESP - Botucatu (SP) Brasil., Alves LR; Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto (SP) Brasil., Cabral Junior BF; Universidade Católica de Brasília, Brasília (DF) Brasil., Carvalho CRR; Faculdade de Medicina, Universidade de São Paulo, São Paulo (SP) Brasil., Cezare TJ; Faculdade de Medicina de Botucatu, Universidade Estadual Paulista - UNESP - Botucatu (SP) Brasil., Costa CHD; Universidade do Estado do Rio de Janeiro - UERJ - Rio de Janeiro (RJ) Brasil., Gazzana MB; Universidade Federal do Rio Grande do Sul - UFRGS - Porto Alegre (RS) Brasil., Jezler S; Hospital Geral Roberto Santos, Salvador (BA) Brasil., Kairalla RA; Faculdade de Medicina, Universidade de São Paulo, São Paulo (SP) Brasil., Kawano-Dourado L; Instituto de Pesquisa. Hospital do Coração, São Paulo (SP) Brasil., Lima MS; Universidade Federal do Ceará, Fortaleza (CE) Brasil., Mancuzo E; Universidade Federal de Minas Gerais, Belo Horizonte (MG) Brasil., Moreira MAC; Universidade Federal de Goiás, Goiânia (GO) Brasil., Rodrigues MP; Universidade de Brasília - UnB - Brasília (DF) Brasil., Rodrigues SCS; Hospital do Servidor Público Estadual de São Paulo, São Paulo (SP) Brasil., Rubin AS; Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre (RS) Brasil., Rufino RL; Universidade do Estado do Rio de Janeiro - UERJ - Rio de Janeiro (RJ) Brasil., Steidle LJM; Universidade Federal de Santa Catarina - UFSC - Florianópolis (SC) Brasil., Storrer K; Universidade Federal do Paraná - UFPR - Curitiba (PR) Brasil., Baldi BG; Faculdade de Medicina, Universidade de São Paulo, São Paulo (SP) Brasil. |
| Abstrakt: |
Idiopathic pulmonary fibrosis (IPF) is a form of chronic interstitial lung disease of unknown cause, which predominantly affects elderly men who are current or former smokers. Even though it is an uncommon disease, it is of great importance because of its severity and poor prognosis. In recent decades, several pharmacological treatment modalities have been investigated for the treatment of this disease, and the classic concepts have therefore been revised. The purpose of these guidelines was to define evidence-based recommendations regarding the use of pharmacological agents in the treatment of IPF in Brazil. We sought to provide guidance on the practical issues faced by clinicians in their daily lives. Patients of interest, Intervention to be studied, Comparison of intervention and Outcome of interest (PICO)-style questions were formulated to address aspects related to the use of corticosteroids, N-acetylcysteine, gastroesophageal reflux medications, endothelin-receptor antagonists, phosphodiesterase-5 inhibitors, pirfenidone, and nintedanib. To formulate the PICO questions, a group of Brazilian specialists working in the area was assembled and an extensive review of the literature on the subject was carried out. Previously published systematic reviews with meta-analyses were analyzed for the strength of the compiled evidence, and, on that basis, recommendations were developed by employing the Grading of Recommendations Assessment, Development and Evaluation approach. The authors believe that the present document represents an important advance to be incorporated in the approach to patients with IPF, aiming mainly to improve its management, and can become an auxiliary tool for defining public policies related to IPF. |
